Lobak

Quick links to important sections

Lobak

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lobak

What is Lobak? Classification and Purpose

Property Description
Active Ingredients Acetaminophen, Chlormezanone
Form Solid Oral Formulation (Tablet/Capsule)
Pharmacological Class Analgesic, Skeletal Muscle Relaxant
Common Use Relief of Pain and Muscle Tension
Origin Synthetic Compound

Lobak is a synthetic Fixed-Dose Combination (FDC) medicine, recognized within the Analgesic and Skeletal Muscle Relaxant pharmacological class. It is engineered as a compound pharmacotherapeutic agent intended to provide relief for symptoms that involve both the sensation of pain and accompanying muscle tension. The strategic combination approach, supported by pharmacological review, is clinically recognized for addressing discomfort where both muscular tightness and pain are factors.

This medication’s core identity stems from its dual-action approach, differentiating it from simpler monotherapy preparations. The combined strategy allows Lobak to address the overall discomfort profile where involuntary muscle contraction or stiffness contributes to the patient's symptoms, serving the general purpose of providing broad symptomatic relief.


Active Ingredients: Composition of the Combination Drug

The preparation contains two distinct active ingredients: Acetaminophen (or Paracetamol) and Chlormezanone. Acetaminophen is a widely established non-opioid analgesic and antipyretic, while Chlormezanone functions as a central nervous system depressant with muscle relaxant and anxiolytic properties. This particular formulation is often positioned for managing discomfort related to conditions like tension or strain.

Lobak is supplied as a solid oral formulation, typically a tablet or capsule. Both active compounds are synthetic in origin, and the FDC structure ensures a precise and standardized delivery of both the analgesic and the muscle relaxant via the oral route of administration.


Distinguishing Lobak: Dual Action Versus Monotherapy

Lobak is functionally distinguished from basic pain relievers (monotherapy) by its combined physiological action. While the Acetaminophen component works primarily within the central nervous system to reduce pain awareness, the Chlormezanone component exerts a calming effect on nerve activity, which directly helps in easing the tone and stiffness of skeletal muscles.

This dual action system offers a clear functional advantage. By simultaneously targeting pain signals and muscular hyperactivity, the formulation is specifically designed to manage discomfort where both factors are present. This approach makes it a clinically effective option for scenarios involving musculoskeletal tension where the secondary benefit of mild central calming is desired.

Regulatory References

  1. MedlinePlus: Acetaminophen Information

What side effects are possible with Lobak?

Possible Side Effects and Safety Information

The official safety profile for this fixed-dose combination (FDC) medicine describes documented adverse reactions primarily concerning the Central Nervous System (CNS) and the risk of Hepatotoxicity associated with the acetaminophen component.


Adverse Reaction Scope

The frequency of documented effects is structurally defined by regulatory categories, with many effects falling under the Nervous System Disorders and Gastrointestinal Disorders system-organ classes.

Category Documented Effects/Classifications
Commonly Reported Drowsiness, dizziness, lightheadedness, nausea, vomiting, headache.
Serious Adverse Reactions The most critical risk is Acute Liver Failure (sometimes resulting in liver transplant or death) associated with acetaminophen, particularly when maximum dosage is exceeded. Rare but severe Immunologic Skin Reactions are also documented.
System-Organ Classes Nervous System, Gastrointestinal, Hepatobiliary, and Skin and Subcutaneous Tissue Disorders.

Safety-Related Constraints

The official labeling specifies important limitations on use:

  • Contraindications: The medicine is contraindicated in patients with known hypersensitivity to the active ingredients or those with severe hepatic impairment or severe active liver disease.
  • Population Notes: Caution is advised for patients with chronic malnutrition or who regularly consume alcohol due to the increased risk of severe liver damage. Caution is also noted for older adults due to increased susceptibility to CNS effects.
  • Additive CNS Effects: A high-level restriction is placed on concurrent use with alcohol or other Central Nervous System depressants, as this may intensify effects such as drowsiness and dizziness.

This framework establishes the medicine's constraints and potential adverse effects based exclusively on governmental regulatory documentation.

Overdose and Emergency Response

A Lobak overdose is officially classified in regulatory documents as a potentially severe, life-threatening emergency primarily due to its dual toxicological profile. The key risk areas involve the hepatic and central nervous systems.

Early manifestations of overdose may be non-specific, often including nausea, vomiting, sweating, and general malaise. However, due to the Acetaminophen component, overdose can progress to severe hepatic necrosis and acute liver failure, presenting later with signs like jaundice and abdominal pain. The Chlormezanone component carries the additional risk of central nervous system depression, leading to profound sedation, confusion, and respiratory depression, which may result in coma.

Regulatory bodies mandate that individuals seek immediate medical attention or contact a certified Poison Control Center right away for any suspected ingestion exceeding the recommended dose, even if no symptoms are immediately apparent. This urgency is critical because the most severe outcomes are often delayed. Management in overdose situations requires prompt testing of serum concentrations and continuous hospital monitoring of both liver function and neurological status. The antidote, N-acetylcysteine, is an essential treatment explicitly cited in official labeling to minimize or prevent severe hepatic injury.

Therapeutic Uses of Lobak

What Lobak Treats: Main Uses and Benefits

Lobak is commonly used to help provide symptomatic relief across therapeutic domains where physical discomfort arises from the combination of pain and associated muscle activity. This approach is considered relevant when supportive symptom management is appropriate in contexts marked by increased discomfort or tension.

The medication is generally applied in conditions characterized by periods of heightened symptoms, such as acute musculoskeletal discomfort and tension-related manifestations. This helps address symptom clusters that may become intense or disruptive.

“The medication is intended to offer symptomatic relief, assisting patients in coping more steadily with difficult episodes of discomfort.”

Dual Relief for Pain and Muscle Spasm

Given the dual therapeutic approach, the medication is commonly applied in clinical settings where acute physical discomfort is associated with pronounced muscle tightness or stiffness. A primary therapeutic benefit includes supportive relief, which may help ease the overall symptom burden when both pain and muscular tightness are present. Lobak is commonly applied across conditions presenting with episodic manifestations of tension, supporting improved day-to-day comfort during symptomatic periods.


Quick Fact: Supportive Management of Musculoskeletal Tension


Regulatory References

  1. Health Canada Product Monograph on FDC Muscle Relaxants and Analgesics

Eligibility and Restrictions for Use

The official regulatory profile for Lobak is defined by specific population restrictions stemming from its two active components, Acetaminophen and Chlormezanone. Use is generally established for the adult population under standard labeled conditions, but the profile mandates strict limitations on several groups.

Eligibility Status Defined Populations
Contraindicated Patients with severe hepatic impairment or severe active liver disease. Individuals with known hypersensitivity to Acetaminophen, Chlormezanone, or any components of the medicine.
Use with Caution Geriatric patients (older adults) due to increased susceptibility to central nervous system (CNS) effects. Patients with a history of depression or other psychiatric disorders. Individuals with chronic alcohol use, chronic malnutrition, or severe renal impairment.

The drug's use is generally established for adults and adolescents aged 12 years and older. However, official regulatory documents state that use is not established or restricted in children under 12 years due to insufficient safety and efficacy data for the combination drug. Furthermore, use during pregnancy and lactation is generally not recommended or advised only after careful review, given the restricted data for the combination drug in these physiological states. These constraints define who can and cannot use the medicine according to governmental labeling.

What should I know about interactions with other medicines?

The official regulatory profile for Lobak (Acetaminophen and Chlormezanone) documents specific interaction patterns across several medicinal product categories and substances, classifying these as clinically significant or contraindicated restrictions.

Category Official Interaction Statement/Classification
Central Nervous System (CNS) Depressants Co-administration leads to additive CNS depression (Pharmacodynamic interaction due to Chlormezanone component).
Anticoagulants (e.g., Warfarin) Chronic, high-dose co-administration with Acetaminophen is documented to cause an increase in International Normalized Ratio (INR).
Metabolic Regulators (e.g., CYP2E1 Inducers) May alter Acetaminophen metabolism and increase the drug’s hepatotoxic potential.
Alcohol and Other Acetaminophen Products Alcohol significantly increases the risk of severe liver damage. The drug is subject to a mandatory restriction prohibiting co-administration with any other product containing acetaminophen.
Population-Specific Interaction Notes The product is contraindicated in patients with severe hepatic impairment due to a heightened risk of toxicity from impaired drug metabolism.

The regulatory interaction structure is defined by pharmacodynamic augmentation and pharmacokinetic risk. Pharmacodynamic augmentation involves additive CNS effects with other CNS depressants and alcohol. The pharmacokinetic profile highlights risks tied to Acetaminophen metabolism, mandating a strict prohibition against combining with other acetaminophen sources to prevent hepatic injury. This official profile also notes the potential for increased INR when used with certain anticoagulants, particularly under conditions of chronic, high-dose use.

Mechanism of Action

Central Pharmacodynamic Mechanism of Lobak

The function of Lobak is defined by the complementary action of its two components on distinct systems: nociceptive signaling and motor control.


Central Modulation of Nociceptive Signal Transmission

The Acetaminophen component exerts its influence primarily within the Central Nervous System (CNS) to modulate nociceptive signaling. Its mechanism involves the central inhibition of Cyclooxygenase (COX) activity and the action of its metabolite, AM404. The metabolite activates the central γ-Aminobutyric acid B (CB₁) and Transient Receptor Potential Vanilloid 1 (TRPV1) receptors, initiating descending signals that interfere with the transmission of pain impulses. This results in reduced sensitivity to nociceptive stimuli via CNS pathway modulation. This mechanism is characterized by its central locus of action, with negligible influence on peripheral inflammation.


Enhancement of GABAA Receptor Inhibition and Motor Reflex Depression

The Chlormezanone component acts as a Positive Allosteric Modulator of the inhibitory GABAA receptor, potentiating the effects of the neurotransmitter GABA. This enhancement of central inhibition leads to generalized neuronal hyperpolarization, which causes depression of the spinal polysynaptic reflex arcs. This physiological change reduces the excessive neuronal firing that maintains muscle tone, leading to the physiological consequence of lowered muscle tone and widespread central neuronal hyperpolarization. The parallel modulation of both nociceptive signal processing and motor output systems defines the overall effect profile of the combination.

Dosage and Administration Information

How to Use Lobak

Lobak, a Fixed-Dose Combination (FDC) of Acetaminophen and Chlormezanone, is administered exclusively via the oral route as a solid oral formulation (tablet or capsule).


Official Administration Guidelines

Feature Official Instruction or Pattern
Route of administration The medication is taken orally.
Dosing schedule The standard regimen is defined by a unit dose, typically administered four times daily.
Timing in relation to meals May be taken with or without food. Administration with food or milk is a general consideration for tolerability.
Preparation requirements The solid unit requires no prior preparation and must be swallowed whole.
Course duration Intended for short-term use for the management of acute symptomatic episodes.

Usage Constraints and Adjustments

Established parameters for the use of this FDC are primarily governed by the constraints of the analgesic component. The dose of Acetaminophen supplied by Lobak must be included when calculating the total daily intake from all sources, which must not exceed 4,000 mg in a 24-hour period.

The protocol also requires mandatory dosage reduction or adjustment for specific patient populations. Dosage modification is necessary for individuals with documented hepatic impairment (liver disease) or renal impairment (kidney disease). This administration pattern is consistent with the established structure for FDC analgesics and muscle relaxants.

Recent Clinical Evidence

Research evidence / Overview of Studies for Lobak


Evidence for Acute Musculoskeletal Pain Associated with Muscle Spasm

Research has examined fixed-dose combinations (FDCs) containing an analgesic (like acetaminophen) and a central muscle relaxant in the context of symptom patterns related to physical discomfort associated with muscle tightness. These agents was studied for conditions characterized by fluctuating or episodic manifestations, such as sudden or acute low back pain and muscle strains. The primary evidence base consists mainly of short-term randomized studies (RCTs) and subsequent Systematic Reviews that aggregated findings across multiple studies.

In these trials, researchers primarily monitored short-term changes in outcomes related to physical discomfort, specifically measuring pain intensity using standard rating scales. Studies have described patterns where the combination group registered specific short-term measurements for pain and spasm relief when compared to other groups (monotherapy or placebo) during the acute treatment period.

Data on long-term effects are not fully established for this combination. The research highlights changes measured over study durations which were typically limited to seven days or less, reflecting the acute nature of the studied conditions. Consequently, the follow-up durations were limited, and data are still emerging regarding how symptoms evolve after the initial treatment period.


Research on Other Symptomatic Manifestations (e.g., Tension Headache)

The combination or similar agents were observed in research exploring other painful conditions, such as episodic tension-type headache. These studies research examined how symptoms change over time following a single dose. The evidence for these secondary uses is less extensive compared to that for acute muscle spasm. Studies focusing on episodes where symptoms become more noticeable exist, but the sample sizes were modest and the follow-up durations were limited to the immediate response phase.


What Remains Uncertain in the Research Landscape

Several limitations and gaps exist in the current research for this combination. The follow-up durations were limited, creating a need for more research to fully understand sustained outcomes. The evidence quality varies across studies, particularly older ones, and sample sizes were modest in some specific FDC trials. Furthermore, data on long-term effects are not fully established, and comparative evidence is lacking for many potential head-to-head comparisons against newer treatments. Overall, the research structure helps show what has been observed so far in acute settings, but evidence highlights what is known — and what is still uncertain — especially concerning long-term use, certain populations, and the consistency of all findings.

Key Studies & References

  1. Oral non-benzodiazepine muscle-relaxants for people with acute and chronic primary low back pain: a systematic review with meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Lobak (FAQ)

Q: Does Lobak treat the symptoms or the underlying cause?

A: According to official product descriptions, Lobak is intended to provide symptomatic relief for physical discomfort and accompanying muscle tension. The medication helps manage the symptoms you are currently experiencing, but it is not described as treating the underlying condition that caused them.

Q: Are there any long-term side effects associated with taking Lobak?

A: Official research evidence indicates that studies on this specific combination were typically limited to short durations, often seven days or less. While long-term data for the combination are not fully established, warnings are present regarding the acetaminophen component's potential for severe liver damage with chronic or high-dose use.

Q: Is Lobak considered a safe medicine for older adults?

A: Regulatory documents advise caution when this medicine is used by older adults. This is due to a potential increased sensitivity to the effects on the Central Nervous System (CNS), which may include effects like drowsiness or dizziness.

Q: Can Lobak be used by people with kidney problems?

A: Official protocols establish that dosage modification is necessary for individuals with documented renal impairment, or kidney disease. This adjustment is required to ensure the medicine is processed consistently by the body.

Q: What is the risk of having a serious allergic reaction to Lobak?

A: This medicine is contraindicated, meaning it should not be used, by anyone with a known hypersensitivity or severe allergy to its components. Furthermore, official safety information documents the rare occurrence of severe immunologic skin reactions.

Q: Are there any common foods or drinks that should be avoided while taking Lobak?

A: Official labeling includes a mandatory restriction against co-administering the medicine with alcohol, as this significantly increases the risk of severe liver damage. Beyond alcohol, the official guidelines state that the medicine can generally be taken with or without food.

Q: Does Lobak interact with common over-the-counter pain relievers?

A: Yes, official product information contains a mandatory restriction against combining Lobak with any other product containing acetaminophen. This prohibition is in place to prevent accidental overdose and subsequent increased risk of liver damage.

Q: Can taking Lobak affect my mood or sleep?

A: Common documented adverse effects include drowsiness, which may affect sleep patterns. The medicine also exerts effects on the Central Nervous System (CNS), and official population notes advise caution for individuals with a history of depression.

Q: Is Lobak used for any conditions other than the main ones listed in its official documentation?

A: Official indications define the approved use as the relief of pain and muscle tension associated with musculoskeletal conditions. Any potential use for other conditions, such as those sometimes explored in research, is not the officially defined purpose.

Q: Are there any specific activities to avoid when using Lobak?

A: Because the medicine commonly causes drowsiness and dizziness, caution is advised for activities that require high mental alertness. This includes tasks such as driving, operating heavy machinery, or any activity where impaired concentration could be hazardous.

Q: Does Lobak have an 'on-demand' or a continuous daily use schedule?

A: Official protocols define a standard fixed schedule for this medicine. The standard regimen is defined by a unit dose for short-term use, typically administered four times daily for managing acute, symptomatic episodes.

Q: Is there a maximum time someone can safely use Lobak?

A: The medication is intended strictly for short-term use in acute settings. The research evidence that supports this combination was typically drawn from studies limited to durations of seven days or less.

Q: What should I do if I miss a dose of Lobak?

A: Official patient information typically outlines a general procedure for a missed dose, stating that the dose should be taken as soon as it is remembered. However, if that time is close to the next scheduled dose, the guideline often indicates that the missed dose should be passed, and the person should return to their regular schedule.

Q: How long does it typically take for Lobak to start having an effect?

A: The analgesic component, acetaminophen, typically reaches its peak concentration in the body within one to two hours after taking the medicine by mouth. This point is often related to when the effects of the component are first noticed.

Q: After starting Lobak, when might I notice the maximum benefit?

A: In clinical trials, researchers often measured the peak effect for pain relief around the four-hour mark following a single dose. The maximum benefit observed in studies typically correlates with the time the components reach their highest activity.

Q: Does Lobak build up in the body over time?

A: The active components are generally eliminated from the body within 24 hours. This pharmacokinetic profile is consistent with medicines not expected to significantly build up or accumulate in the body when used according to the established four-times-daily schedule.

Q: Can Lobak be taken with vitamin supplements or herbal products?

A: Official regulatory documents prioritize detailing interactions with other prescription medicines and alcohol. Specific information regarding interactions with all possible vitamin supplements or herbal products may not be fully established in the primary labeling.

Q: Are there any common tests or lab work that Lobak might interfere with?

A: Yes, the acetaminophen component of Lobak is documented to potentially interfere with the accuracy of certain common laboratory tests. This interference may affect results for substances such as glucose (blood sugar) and uric acid.

Q: What does the official information say about stopping Lobak use?

A: Because the official protocol dictates the use of this medicine only for acute, short-term treatment, the regulatory text does not specify a mandatory tapering schedule. This suggests that the medicine is generally not intended to be stopped gradually when used for its approved duration.

Q: Is Lobak known to be a habit-forming or addictive medicine?

A: Official regulatory labeling includes a dedicated section on Drug Abuse and Dependence. This section addresses the potential for a medicine to be misused or to lead to habit formation.

Q: Does Lobak come in different strengths or forms?

A: The medication is supplied as a solid oral formulation, which may be a tablet or a capsule. The official label specifies the precise and fixed strengths of the two active ingredients contained within each unit dose.

Q: Is it important to take Lobak at the exact same time every day?

A: The medicine is prescribed on a fixed schedule, typically to be taken multiple times a day. This consistent timing is necessary to maintain stable levels of both active components in the body, helping to ensure continuous symptomatic relief throughout the day.

Q: How is Lobak eliminated from the body?

A: The process by which the body breaks down the medicine starts in the liver, where the active components are metabolized. The resulting compounds are then primarily eliminated from the body by the kidneys through the urine.

Q: Are there any official documents that summarize the research findings for Lobak?

A: Yes, official regulatory documents, such as the FDA Prescribing Information, contain a dedicated section that summarizes the key clinical studies and research evidence used to support the medicine's official uses and approval.

Q: Can Lobak affect fertility?

A: The official regulatory profile includes a review of reproductive and fertility data for the individual active components. However, for the combination medicine, information regarding potential effects on fertility may be limited or not fully established in the primary product label.

How should Lobak be stored and disposed of?

How to Store and Dispose of Lobak?

The official storage and disposal requirements for Lobak (Acetaminophen, Chlormezanone) are documented to ensure product stability and household safety.

Storage Conditions

Requirement Specification
Temperature Store at Controlled Room Temperature, typically 20^circC to 25^circC (68^circF to 77^circF).
Protection Protect from moisture and excessive heat; do not store in high-humidity areas like a bathroom.
Container Keep the medicine in its original container and ensure the container is tightly closed to maintain stability.
Child Safety Keep out of the sight and reach of children at all times.

Disposal Instructions

Expired or unused Lobak must be disposed of safely. Do not flush the product down the toilet or pour it down a drain. The medicine should be disposed of via a community drug take-back program or, if unavailable, by following guidelines for household trash disposal to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lobak found in:

A-Z Index: